Bruker (NASDAQ:BRKR) Rating Reiterated by Bank of America

Bank of America reissued their neutral rating on shares of Bruker (NASDAQ:BRKR) in a research report released on Friday morning, Briefing.com Automated Import reports. The brokerage currently has a $52.00 price objective on the medical research company’s stock, up from their previous price objective of $44.00.

Other equities research analysts also recently issued research reports about the stock. Jefferies Financial Group boosted their price objective on shares of Bruker from $45.00 to $56.00 and gave the company a buy rating in a research report on Friday. BTIG Research boosted their price objective on shares of Bruker to $57.00 and gave the company a buy rating in a research report on Friday. BidaskClub raised shares of Bruker from a hold rating to a buy rating in a research report on Wednesday, June 5th. Deutsche Bank raised shares of Bruker from a hold rating to a buy rating and boosted their target price for the company from $40.00 to $50.00 in a research note on Friday, April 12th. Finally, Zacks Investment Research lowered shares of Bruker from a buy rating to a hold rating in a research note on Tuesday, April 16th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $47.10.

Shares of NASDAQ:BRKR opened at $48.76 on Friday. The company has a quick ratio of 1.27, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. Bruker has a fifty-two week low of $26.10 and a fifty-two week high of $48.88. The stock has a market cap of $7.65 billion, a P/E ratio of 34.83, a price-to-earnings-growth ratio of 2.47 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. Bruker had a net margin of 9.53% and a return on equity of 26.28%. The business had revenue of $461.40 million during the quarter, compared to the consensus estimate of $450.46 million. During the same quarter in the prior year, the firm earned $0.24 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, equities analysts expect that Bruker will post 1.62 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 21st. Shareholders of record on Monday, June 3rd were paid a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date of this dividend was Friday, May 31st. Bruker’s payout ratio is 11.43%.

In other Bruker news, CEO Frank H. Laukien sold 400,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $41.48, for a total transaction of $16,592,000.00. Following the completion of the transaction, the chief executive officer now directly owns 37,991,030 shares of the company’s stock, valued at approximately $1,575,867,924.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Marc A. Kastner sold 1,374 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total transaction of $57,419.46. Following the transaction, the director now directly owns 10,811 shares of the company’s stock, valued at $451,791.69. The disclosure for this sale can be found here. Insiders have sold a total of 801,374 shares of company stock valued at $33,241,419 over the last three months. 26.50% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of BRKR. O Shaughnessy Asset Management LLC acquired a new stake in shares of Bruker in the 1st quarter worth approximately $35,000. Captrust Financial Advisors raised its holdings in shares of Bruker by 164.7% during the fourth quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 1,135 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Bruker during the fourth quarter valued at approximately $176,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in shares of Bruker during the fourth quarter valued at approximately $192,000. Finally, ARP Americas LP acquired a new stake in shares of Bruker during the first quarter valued at approximately $212,000. 66.73% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Further Reading: What is the quiet period?

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.